← Leaderboards
Christopher S Carlson
Fred Hutchinson Cancer Research Center
$5,755,749
Attributed
$9,151,993
Total exposure
7
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.9M · FY2006–20$5M$3.8M$2.5M$1.3M$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
Funding mix
By agency
NIH$9,151,993 · 7
By mechanism
R01$3,977,780 · 2
UC2$2,411,094 · 1
RC2$2,117,232 · 1
R21$421,080 · 1
R03$170,492 · 1
P50$54,315 · 1
Top collaborators
- Rebecca D Jackson2 shared
- Kari E North2 shared
- Ulrike Peters2 shared
Most similar at Fred Hutchinson Cancer Research Center
Same institution · by research overlap
- Galina N Filippova$4,575,431
- Ulrike Peters$61,091,539
- Anne M McTiernan$13,216,472
Others in their field
Top investigators on “Sampling”
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Jeffrey P Krischer · University Of South Florida$522,319,685
- David R. Weir · University Of Michigan At Ann Arbor$421,002,438
- David Heimbrook · Leidos Biomedical Research, Inc.$410,224,927
- Eric S Lander · Whitehead Institute For Biomedical Res$395,613,296
- Richard A Gibbs · Baylor College Of Medicine$356,778,395
Research focus
SamplingGeneticGenotypePrognosticElderlyLeadReportingPathway InteractionsStagingMalignant NeoplasmsAllelesTumorPublic Health RelevanceAffectLibrariesAmericanLightRisk FactorsPhenotypeDna ResequencingCellsBiologicalMeasurementB-Lymphocytes
Grant awards (22)
Monitoring disease progression in follicular lymphoma with next-gen sequencing$226,306
R01 · FY2020 · CA · contact PI
Monitoring disease progression in follicular lymphoma with next-gen sequencing$140,842
R01 · FY2020 · CA · contact PI
Monitoring disease progression in follicular lymphoma with next-gen sequencing$935,354
R01 · FY2019 · CA · contact PI
Monitoring disease progression in follicular lymphoma with next-gen sequencing$1
R01 · FY2018 · CA · contact PI
Impact of primary tumor development stage on prognosis and outcome in B-ALL$100,931
R21 · FY2017 · CA · contact PI
Monitoring disease progression in follicular lymphoma with next-gen sequencing$691,364
R01 · FY2016 · CA · contact PI
Monitoring disease progression in follicular lymphoma with next-gen sequencing$513,853
R01 · FY2015 · CA · contact PI
Impact of primary tumor development stage on prognosis and outcome in B-ALL$90,469
R21 · FY2015 · CA · contact PI
Impact of primary tumor development stage on prognosis and outcome in B-ALL$229,680
R21 · FY2014 · CA · contact PI
GENETICS$2,566
P50 · FY2014 · CA · contact PI
GENETICS$43,839
P50 · FY2013 · CA · contact PI
GENETICS$2,569
P50 · FY2012 · CA · contact PI
GENETICS$2,680
P50 · FY2011 · CA · contact PI
WHI Sequencing Project (WHISP)$2,411,094
UC2 · FY2010 · HL
Assessing the Impact of Rare Polymorphism at CRP on CRP Levels & Atherosclerosis$440,000
R01 · FY2010 · HL · contact PI
GENETICS$2,661
P50 · FY2010 · CA · contact PI
WHI Sequencing Project (WHISP)$2,117,232
RC2 · FY2009 · HL
Assessing the Impact of Rare Polymorphism at CRP on CRP Levels & Atherosclerosis$421,380
R01 · FY2009 · HL · contact PI
Assessing the Impact of Rare Polymorphism at CRP on CRP Levels & Atherosclerosis$251,520
R01 · FY2009 · HL · contact PI
Assessing the Impact of Rare Polymorphism at CRP on CRP Levels & Atherosclerosis$357,160
R01 · FY2008 · HL · contact PI
Evolutionary analysis of CTCF and potential links to breast cancer phenotypes$83,992
R03 · FY2007 · CA · contact PI
Evolutionary analysis of CTCF and potential links to breast cancer phenotypes$86,500
R03 · FY2006 · CA · contact PI